Anomia Therapy and Executive Function Training in Chronic Post-stroke Aphasia: Pilot Study of Mul… (NCT06712225) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Anomia Therapy and Executive Function Training in Chronic Post-stroke Aphasia: Pilot Study of Multidimensional Effects
8 participantsStarted 2025-01
Plain-language summary
The goal of this clinical trial is to measure the effects of a speech therapy protocol combining anomia therapy and executive function training on naming and discourse in people with chronic aphasia, and to study the related brain changes.
The main questions it aims to answer are:
* Does the protocol improve naming skills ?
* Do the improvements observed transfer to discourse abilities ?
* Are there any brain changes induced by this protocol ?
Researchers will compare anomia therapy alone to anomia therapy + executive function training to see if the latter works better.
Participants will:
* Have a whole language assessment and a Magnetic Resonance Imaging (MRI) scan in the hospital before and after the protocol
* Receive 18 sessions of the protocol, 3 times a week during 6 weeks, in the hospital
* Have several naming assessments during the protocol
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult (18-80 years old) with post-stroke aphasia (\> 6 months post-stroke)
* Participant or legal representative able to understand the aims of the study
* Participant or legal representative who have signed an informed consent form
Exclusion Criteria:
* Aphasia with severe anarthria (mutism), comprehension disorders or alexia, incompatible with the purpose of the study
* Contraindications for MRI
* History of head trauma, brain tumor, neurodegenerative disease, or any other neurological or psychiatric condition
* Non-affiliation to social welfare
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in repeated measures of naming scores
Timeframe: Every 2 or 3 sessions during the baseline phase (3 sessions per week during 3,5 to 5 weeks) and during the experimental phase (3 sessions per week during 6 weeks)